Drugs / Anti-CEA-CAR T
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04513431 | Aug 2020 → Mar 2021 | metastasis from malignant tumor of colon | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02850536 | Feb 2017 → Dec 2018 | — | Roger Williams Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02349724 | Dec 2014 → Dec 2018 | breast cancer, colorectal cancer, gastric cancer, lung cancer +1 | Southwest Hospital, China | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CEA-CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04513431 ↗ |
| Action | Deplete | “Preclinical studies have demonstrated effective killing of CEA target cells.” NCT02349724 ↗ |
| Modality | Cell therapy | “anti-CEA CAR-modified T cells” NCT02349724 ↗ |